Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL22 Retreatment in Relapsed/Refractory Hairy Cell Leukemia
NCT00924040Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Feb 2009
- Primary completion
- Aug 2010
- Modality
- Antibody Fragments, Antibody-Drug Conjugates (ADCs), Immunotoxins
- Countries
- 1
01
Overview
A Phase 2 trial of BL22 in hairy cell leukemia (HCL), sponsored by National Cancer Institute. Started Feb 2009; status: terminated.
02
Drugs
BL22
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT00924040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00924040.